Shockwave Medical (SWAV) Tops Q4 EPS, Revenue; Guides Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip rally offsets renewed Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices dive by more than 2% as inflation fears outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Shockwave Medical Reports Fourth Quarter and Full Year 2022 Financial Results
February 16, 2023 4:02 PM ESTSANTA CLARA, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2022.
Recent Highlights
Recognized revenue of $144.0 million for the fourth quarter of 2022 and $489.7 million for the full year 2022, representing increases of 71% and 107%, respectively, from the same periods in 2021Received FDA approval for the Shockwave C2+ Coronary IVL Catheter in the... More